In patients with intraductal carcinoma, the incidence of BRCA2 germline mutations reported in the literature is higher than for adenocarcinoma, while the data for somatic mutations are similar to the rest of patients with prostatic carcinoma [19,20]. The gene discussed is BRCA2; the disease is adenocarcinoma.